MALAT1 and metabolic syndrome: Interestingly, MALAT1 was found to be significantly reduced in serum-derived EVs from individuals with metabolic syndrome (MetS), that agglomerates the co-occurrence of a number of conditions such as central obesity, dislipedimia and hypertension that greatly increase the risk of T2DM and cardiovascular diseases (105).